Pharma
Pharma launches in the precision medicine space depend on diagnostics infrastructure that gets built years before the first prescription. The CDx partner committed to, the lab capacity that will absorb the launch, the markets ready for the asset, the disease areas where the testing infrastructure can carry the strategy — these are decisions that lock in long before the commercial team is staffed, and they shape whether the asset reaches patients on the timeline the pipeline assumes.

Select Capabilities
Biomarker and Diagnostics Strategy
This is where precision medicine starts – whether you’re trying to find the right tools to uncover new biomarkers, identify CDx partners, launch an IVD, or understand how your assay will fit into the clinical journey, DeciBio has you covered. Nobody knows biomarkers and CDx better than DeciBio.
Selected Work

Cell Therapy Market Trends and Revenue Forecast
Revenue Projection

Cell and Gene Therapy Services Landscape Assessment
Market Landscaping and Sizing

Biopharma Genomic Testing Market Research
Voice-of-Customer Research





.png)

.png)
.png)


